JP6670763B2 - 治療用途のための一酸化炭素放出分子ならびにその作製および使用の方法 - Google Patents

治療用途のための一酸化炭素放出分子ならびにその作製および使用の方法 Download PDF

Info

Publication number
JP6670763B2
JP6670763B2 JP2016571722A JP2016571722A JP6670763B2 JP 6670763 B2 JP6670763 B2 JP 6670763B2 JP 2016571722 A JP2016571722 A JP 2016571722A JP 2016571722 A JP2016571722 A JP 2016571722A JP 6670763 B2 JP6670763 B2 JP 6670763B2
Authority
JP
Japan
Prior art keywords
group
aryl
heteroaryl
cycloalkyl
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016571722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528416A (ja
JP2017528416A5 (enExample
Inventor
ビンヘ ワン，
ビンヘ ワン，
ダンツ ワン，
ダンツ ワン，
シンユ ジ，
シンユ ジ，
アレクサンダー ドラガノフ，
アレクサンダー ドラガノフ，
チャオフェン ダイ，
チャオフェン ダイ，
クリシュナ ダメラ，
クリシュナ ダメラ，
ディディエ マーリン，
ディディエ マーリン，
エミリー べノアス，
エミリー べノアス，
ユチン ゼン，
ユチン ゼン，
Original Assignee
ジョージア ステイト ユニバーシティ リサーチ ファンデーション， インコーポレイテッド
ジョージア ステイト ユニバーシティ リサーチ ファンデーション， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジョージア ステイト ユニバーシティ リサーチ ファンデーション， インコーポレイテッド, ジョージア ステイト ユニバーシティ リサーチ ファンデーション， インコーポレイテッド filed Critical ジョージア ステイト ユニバーシティ リサーチ ファンデーション， インコーポレイテッド
Publication of JP2017528416A publication Critical patent/JP2017528416A/ja
Publication of JP2017528416A5 publication Critical patent/JP2017528416A5/ja
Application granted granted Critical
Publication of JP6670763B2 publication Critical patent/JP6670763B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/40—Carbon monoxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B37/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving either the formation of a carbon-to-carbon bond between two carbon atoms not directly linked already or the disconnection of two directly linked carbon atoms
    • C07B37/10—Cyclisation
    • C07B37/12—Diels-Alder reactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2016571722A 2014-06-09 2015-06-09 治療用途のための一酸化炭素放出分子ならびにその作製および使用の方法 Active JP6670763B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009451P 2014-06-09 2014-06-09
US62/009,451 2014-06-09
PCT/US2015/034948 WO2015191616A1 (en) 2014-06-09 2015-06-09 Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof

Publications (3)

Publication Number Publication Date
JP2017528416A JP2017528416A (ja) 2017-09-28
JP2017528416A5 JP2017528416A5 (enExample) 2018-07-19
JP6670763B2 true JP6670763B2 (ja) 2020-03-25

Family

ID=54834205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016571722A Active JP6670763B2 (ja) 2014-06-09 2015-06-09 治療用途のための一酸化炭素放出分子ならびにその作製および使用の方法

Country Status (8)

Country Link
US (2) US10300069B2 (enExample)
EP (1) EP3151919B1 (enExample)
JP (1) JP6670763B2 (enExample)
KR (1) KR20170007857A (enExample)
CN (1) CN106794362B (enExample)
AU (1) AU2015274767B2 (enExample)
CA (1) CA2950007A1 (enExample)
WO (1) WO2015191616A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191616A1 (en) 2014-06-09 2015-12-17 Georgia State University Research Foundation, Inc. Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof
US11420994B2 (en) 2016-11-16 2022-08-23 Georgia State University Research Foundation, Inc. Carbon-monoxide-releasing molecules and therapeutic applications thereof
KR102373273B1 (ko) * 2017-04-18 2022-03-15 기초과학연구원 고분자형 젤과 이의 제조방법, 및 이를 포함하는 물품
WO2018231841A1 (en) 2017-06-12 2018-12-20 Georgia State University Research Foundation, Inc. Enzyme-triggered carbon monoxide releasing molecules
US20180369278A1 (en) * 2017-06-23 2018-12-27 The Regents Of The University Of Michigan Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease
WO2019032879A1 (en) * 2017-08-09 2019-02-14 Georgia State University Research Foundation, Inc. CARBON MONOXIDE RELEASE MOLECULES DISCHARGED BY PHYSIOLOGICAL STIMULI
WO2019084323A1 (en) 2017-10-25 2019-05-02 Georgia State University Research Foundation, Inc. CHEMICAL RELEASE SYSTEM DELIVERED BY ENRICHMENT
CN109306049B (zh) * 2018-09-28 2020-12-01 中国热带农业科学院农产品加工研究所 植物油-壳聚糖基可生物降解pua及其制备方法和应用
CN113365617B (zh) * 2018-10-16 2025-12-23 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
CN113559071B (zh) * 2021-08-18 2022-12-27 苏州大学 一种co靶向递送系统及其构建方法与应用
EP4275682A1 (en) * 2022-05-12 2023-11-15 Institut National De La Sante Et De La Recherche Medicale - Inserm Carbon monoxide-releasing molecule (corm) or composition thereof for use in the treatment or the prevention of an intestinal dysbiosis in a subject
CN117534840A (zh) * 2022-08-02 2024-02-09 巴迪脉通医疗科技(苏州)有限公司 一种可释放co的医用高分子及其制备方法及应用
WO2025090901A1 (en) * 2023-10-26 2025-05-01 Georgia State University Research Foundation, Inc. Ros-activated co prodrugs for cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670664A (en) * 1995-09-08 1997-09-23 University Of Maryland Biotechnology Institute Photosensitive organic compounds that release carbon monoxide upon illumination
EP2319518A1 (en) 2002-02-04 2011-05-11 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US8519122B2 (en) 2010-02-12 2013-08-27 The Regents Of The University Of California Compositions and methods for modification of biomolecules
WO2015191616A1 (en) 2014-06-09 2015-12-17 Georgia State University Research Foundation, Inc. Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof

Also Published As

Publication number Publication date
EP3151919A1 (en) 2017-04-12
CA2950007A1 (en) 2015-12-17
US10751344B2 (en) 2020-08-25
US20170128456A1 (en) 2017-05-11
WO2015191616A1 (en) 2015-12-17
KR20170007857A (ko) 2017-01-20
EP3151919A4 (en) 2018-02-21
US20190350937A1 (en) 2019-11-21
EP3151919B1 (en) 2023-08-30
AU2015274767B2 (en) 2020-04-16
AU2015274767A1 (en) 2017-01-05
US10300069B2 (en) 2019-05-28
CN106794362B (zh) 2021-07-06
CN106794362A (zh) 2017-05-31
JP2017528416A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
US10751344B2 (en) Carbon monoxide-releasing molecules for therapeutic applications and methods for the preparation and use thereof
US11420994B2 (en) Carbon-monoxide-releasing molecules and therapeutic applications thereof
RU2675270C2 (ru) Сокристаллы и содержащие их фармацевтические композиции
AU2011377440B2 (en) Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof
EP1861403A1 (fr) NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
KR20210102887A (ko) 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
RU2650682C2 (ru) Пирролзамещенное производное индолона, способ его получения, включающая его композиция и применение
CN111566113B (zh) 大环化合物及其用途
TW202021977A (zh) 含有葡糖苷酸衍生物ｊａｋ抑制劑的前藥及其製備方法和應用
JP2025501287A (ja) Ｍｅｎｉｎ阻害剤及びその用途
CN109922834B (zh) 用于治疗癌症的卟啉化合物和组合物
US11730712B2 (en) Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US9771344B2 (en) Peloruside analogs
CN110981888B (zh) N-芳基二硫吡咯酮脲类和氨基酯类衍生物及其制备和应用
WO2004080455A1 (ja) 抗菌剤と抗ガン剤
EP4435060A1 (en) Silicon phthalocyanine and tribenzophthalocyanine dyes and their use in diagnosis and therapy
CN115340526B (zh) 邻二甲酰亚胺类化合物及其药物组合物、制备方法和用途
EP3237015B1 (fr) Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine
JP2019516725A (ja) がんを処置するためのプロパルギル基を含む生体直交型化合物
TWI881296B (zh) 包含抑制前列腺素ｅ２受體之新穎化合物與抗癌藥物的用於治療癌症之藥學組成物
JP2026505742A (ja) 神経系疾患および腫瘍の治療のための多環式化合物
JP2022531612A (ja) がん治療のための新規治療用ベクター及びプロドラッグ
CN111995629A (zh) 大根香叶衍生物及其药物组合物和其在医药中的用途
HK1247906A1 (en) Hydrogen sulfide precursors and conjugates thereof
JP2015137303A (ja) 水溶性ポルフィリン誘導体とそれらの製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200302

R150 Certificate of patent or registration of utility model

Ref document number: 6670763

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250